ACN Newswire
SHANGHAI, July 25, 2025 – (ACN Newswire) – Everest Medicines (HKEX 1952.HK, “Everest” or the “Company”), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that it has entered into a placing and subscription agreement with the placing agents and its controlling shareholder…
Read More
Everest Medicines Announces Share Placement to Raise Approximately HK$1,572.50 Million
Tyisha Mayoral
20:22
SHANGHAI, July 25, 2025 – (ACN Newswire) – Everest Medicines (HKEX 1952.HK, “Everest” or the “Company”), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that it has entered into a placing and subscription agreement with the placing agents and its controlling shareholder…
